Molnupiravir for the Treatment of COVID-19. Information for Patients
Other Language Versions
Abstract
The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to patients. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 replication. It is used for the treatment of mild and moderate COVID-19 in patients who are at high risk of complications, and has shown a significant reduction in the rate of hospitalization or death of patients with COVID-19.
Subject
Collections
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Related items
Showing items related by title, author, creator and subject.
-
(PAHOUnited StatesWashington, D.C., 2022)The Pan American Health Organization presents this information sheet with recommendations on the use of molnupiravir addressed to health professionals. Molnupiravir is a prodrug that significantly inhibits SARS-CoV-2 ...
-
(PAHOUnited StatesWashington, D.C., 2022-05-09)Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression ...
-
(2022-10-18)[RESUMEN]. Con el propósito de describir los cambios en el control de la hipertensión arterial desde 2016 a 2021 y la relación de los progresos con la madurez de implementación de la Iniciativa HEARTS en el primer nivel ...
